Should I Buy ARTV? ARTV 2026 Analysis

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.150

1 Day change

0.97%

52 Week Range

7.360

Analysis Updated At

2026/02/12

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Artiva Biotherapeutics Inc (ARTV) is not a strong buy for a beginner, long-term investor at this time. The lack of positive catalysts, weak financial performance, and neutral technical indicators suggest that waiting for more favorable conditions would be prudent.

Technical Analysis

The MACD is below 0 and negatively contracting, RSI is neutral at 47.057, and moving averages are converging. The stock is trading below the pivot level of 3.94, with support at 3.703 and resistance at 4.177. No clear bullish or bearish trend is indicated.

Positive Catalysts

No significant positive catalysts identified. Hedge funds and insiders are neutral, and there is no recent news or congressional trading activity.

Neutral/Negative Catalysts

is down (-1.54%).

Financial Performance

In Q3 2025, revenue remained at 0, net income improved by 23.21% YoY but is still negative at -21.53M, EPS declined by -4.35% YoY to -0.88, and gross margin dropped to 0 (-100% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for ARTV.

4 Analyst Rating

Wall Street analysts forecast ARTV stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 4.110

Low

Averages

18.67

High

Current: 4.110

Low

Averages

18.67

High

Wedbush

Outperform

maintain

$18 -> $23

AI Analysis

2025-10-17

Reason

Wedbush

Price Target

$18 -> $23

AI Analysis

2025-10-17

maintain

Outperform

Reason

Wedbush raised the firm's price target on Artiva Biotherapeutics to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.

H.C. Wainwright

Emily Bodnar

Buy

initiated

$12

2025-06-11

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$12

2025-06-11

initiated

Buy

Reason

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics with a Buy rating and $12 price target. The company's primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company's various Phase 1/2 studies are positive.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARTV

Unlock Now

ARTV Should I Buy

ARTV Should I Buy

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch